Bru II Venture Capital Fund

Bruin Biometrics (BBI) is a commercial-stage medical technology company focused on the development of sensor-based diagnostic products for the early detection of chronic pressure injuries. The company's flagship product, the Provizio SEM Scanner, is a handheld wireless device that measures sub-epidermal moisture (SEM), a biomarker for early-stage pressure injury. By identifying tissue damage up to five days before it becomes visible on the skin's surface, BBI's technology enables clinicians to implement preventive interventions earlier, significantly reducing the incidence of pressure ulcers. The company serves acute care hospitals, long-term care facilities, and home health agencies globally.